Investment Analysts’ Weekly Ratings Updates for Enovis (ENOV)

Several brokerages have updated their recommendations and price targets on shares of Enovis (NYSE: ENOV) in the last few weeks:

• 11/6/2026 – Enovis had its price target lowered by Canaccord Genuity Group from $45.00 to $42.00. They now have a “buy” rating on the stock.
• 11/6/2026 – Enovis had its price target raised by Wells Fargo & Company from $33.00 to $37.00. They now have an “overweight” rating on the stock.
• 11/5/2026 – Enovis had its price target raised by Needham & Company LLC from $34.00 to $38.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Enovis had its price target raised by BTIG Research from $36.00 to $42.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Enovis was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/31/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/16/2026 – Enovis was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/12/2026 – Enovis had its price target lowered by Needham & Company LLC from $52.00 to $34.00. They now have a “buy” rating on the stock.
• 10/10/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/5/2026 – Enovis had its “buy” rating reaffirmed by UBS Group. They now have a $44.00 price target on the stock.
• 9/28/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/20/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.

Enovis Price Performance

Shares of NYSE ENOV traded down $0.92 during midday trading on Thursday, hitting $27.63. The stock had a trading volume of 1,153,270 shares, compared to its average volume of 1,276,974. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82. The stock has a 50 day simple moving average of $20.21 and a 200-day simple moving average of $23.16. The company has a market capitalization of $1.59 billion, a PE ratio of -3.00 and a beta of 1.31. Enovis Corporation has a 1 year low of $16.70 and a 1 year high of $31.81.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The firm had revenue of $558.73 million during the quarter, compared to analysts’ expectations of $557.12 million. During the same period in the previous year, the business earned $0.75 earnings per share. The firm’s revenue for the quarter was up 1.8% on a year-over-year basis. On average, sell-side analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Insider Transactions at Enovis

In related news, insider Oliver Engert bought 2,660 shares of the stock in a transaction dated Friday, September 4th. The shares were acquired at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the acquisition, the insider directly owned 63,898 shares in the company, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Damien Mcdonald purchased 13,035 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the transaction, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 25,124 shares of company stock valued at $499,517 over the last quarter. Company insiders own 2.90% of the company’s stock.

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.